Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.35 |
| ▸ | ACVRL1 | P37023 | 3/20 | 0.33 |
| ▸ | POLRMT | O00411 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19343962 | 0.90 | CYP2A6 (0.39) | DOT1LACVRL1POLRMTMAP4K4PIK3CD | |
| SCHEMBL18667150 | 0.90 | CYP2A6 (0.39) | DOT1LACVRL1POLRMTMAP4K4PIK3CD | |
| SCHEMBL19344220 | 0.90 | CYP2A6 (0.39) | DOT1LACVRL1POLRMTMAP4K4PIK3CD | |
| SCHEMBL4970560 | 0.90 | CYP2A6 (0.39) | DOT1LACVRL1POLRMTMAP4K4PIK3CD | |
| SCHEMBL19344234 | 0.85 | CYP2A6 (0.39) | DOT1LACVRL1POLRMTMAP4K4PIK3CD | |
| SCHEMBL24058306 | 0.84 | POLRMT (0.35) | DOT1LPOLRMTMAP4K4STING1 | |
| SCHEMBL24340458 | 0.80 | POLRMT (0.43) | DOT1LPOLRMT | |
| SCHEMBL22355531 | 0.80 | POLRMT (0.43) | DOT1LPOLRMT | |
| SCHEMBL24606310 | 0.80 | DOT1L (0.36) | DOT1LPOLRMTPIK3CD | |
| SCHEMBL24606327 | 0.79 | DOT1L (0.34) | DOT1LPOLRMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149049-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20200277321-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2020-09-03 | — | — | US | disclosed |
| WO-2019053696-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277321-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | PNP, RNGTT, NT5C3B | DOT1L 4694/4885ACVRL1 2156/4885POLRMT 79/4885 |
| US-11149049-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, TYMP, SLC29A1 | DOT1L 4140/4885ACVRL1 3303/4885POLRMT 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.